Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Debt: 2011-2025

Historic Non-Current Debt for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Sep 2025 value amounting to $214.9 million.

  • Arrowhead Pharmaceuticals' Non-Current Debt fell 45.35% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.9 million, marking a year-over-year decrease of 45.35%. This contributed to the annual value of $214.9 million for FY2025, which is 45.35% down from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Non-Current Debt is $214.9 million, which was up 7.26% from $200.3 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Non-Current Debt ranged from a high of $407.8 million in Q4 2024 and a low of $200.3 million during Q2 2025.
  • Over the past 2 years, Arrowhead Pharmaceuticals' median Non-Current Debt value was $214.9 million (recorded in 2025), while the average stood at $285.0 million.
  • Data for Arrowhead Pharmaceuticals' Non-Current Debt shows a maximum YoY plummeted of 45.35% (in 2025) over the last 5 years.
  • Arrowhead Pharmaceuticals' Non-Current Debt (Quarterly) stood at $407.8 million in 2024, then crashed by 45.35% to $214.9 million in 2025.
  • Its Non-Current Debt was $214.9 million in Q3 2025, compared to $200.3 million in Q2 2025 and $208.9 million in Q1 2025.